<?xml version="1.0"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
    "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">

<html xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <meta name="generator"
    content="HTML Tidy for FreeBSD (vers 1st April 2002), see www.w3.org" />
    <base
    href="http://www.cirp.org/library/disease/cancer/lehtinen1" />

    <title>Vaccination against human papillomaviruses shows great
    promise</title>
    <meta name="robots" content="index, follow" />
    <meta name="keywords"
    content="cervical cancer, penile cancer, HPV, human papillomavirus, vaccine" />
    <meta name="description"
    content="A medical journal article." />
    <style type="text/css">
/*<![CDATA[*/
<!--
body 
{
background-color: white;
color: black;
}
div.corpus
{
margin-left: 10%;
margin-right: 10%;
font-family: arial, helvetica, sans-serif;
}
p.text1
{
text-align: justify;
font-size: 10.5pt;
}
p.text2
{
text-indent: 2em;
text-align: justify;
font-size: 10.5pt;
}
p.conflicts
{
font-size: 9pt;
}
p.cirp
{
font-weight: bold;
color: navy;
margin-left: 0.8in;
margin-right: 0.8in;
}
ol
{
font-size: 9pt;
}
sup
{
font-size: 7pt;
}
span.comment
{
font-size: 18pt;
}
span.source
{
font-size: 10pt;
}
p.navlink
{
text-align: center;
}
span.yellow
{
background-color: #ff9;
}
p.library
{
font-size: 13pt;
text-align: center;
font-family: "times new roman", times, serif;
font-weight: bold;
}
span.sclibrary
{
font-size: 10pt;
}
-->
/*]]>*/
    </style>
  </head>

  <body bgcolor="white">
    <p class="library">T<span class="sclibrary">HE</span> C<span
    class="sclibrary">IRCUMCISION</span> R<span
    class="sclibrary">EFERENCE</span> L<span
    class="sclibrary">IBRARY</span></p>
    <hr size="1" color="black" />

    <h3>THE LANCET, Volume 364: Pages 1731-2,<br />
     November 13, 2004.</h3>
    <br />
    <br />

    <div class="corpus">
      <table align="right" cellspacing="20" summary="comment">
        <tr>
          <td valign="bottom"><span
          class="comment"><b>Comment</b></span></td>

          <td width="20" bgcolor="navy"><br />
          <br />
          <br />
          <br />
           &nbsp;</td>
        </tr>
      </table>

      <p>&nbsp;</p>
      <br />
      <br />
      <br />
      <br />
      <br />
      <br />
      <br />
      <br />
       
      <hr size="3" color="navy" />

      <h2>Vaccination against human papillomaviruses shows great
      promise</h2>

      <p class="text2">It took almost 10 years from the discovery
      of an association between human papillomavirus (HPV)and
      cervical cancer<sup><a href="#n1">1</a></sup> to the finding
      of HPV type 16 in cervical cancer tissue.<sup><a
      href="#n2">2</a></sup> It took another 10 years to show that
      past infection with HPV16 increases the risk for subsequent
      development of invasive cervical cancer,<sup><a
      href="#n3">3</a></sup> and yet another decade to show that
      the seven most prevalent HPV types cause 87% of all cervical
      cancers.<sup><a href="#n4">4</a></sup> By comparison,the
      creation of HPV virus-like-particle (VLP) vaccines has been a
      rapid breakthrough. VLPs mimic the true structure of the
      virion and induce a striking antibody response after
      vaccination.<sup><a href="#n5">5</a></sup> 2 years ago,
      Koutsky et al<sup><a href="#n6">6</a></sup> showed that
      vaccination with HPV16 VLPs protected 768 vaccinated women
      from persistent HPV16 infection.</p>

      <p class="text2">In today's <i>Lancet</i>, Diane Harper and
      colleagues now expand this rapid development in a <a
      href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6T1B-4DSGXJN-3H&amp;_coverDate=11%2F13%2F2004&amp;_alid=233121028&amp;_rdoc=1&amp;_fmt=&amp;_orig=search&amp;_qd=1&amp;_cdi=4886&amp;_sort=d&amp;view=c&amp;_acct=C000050221&amp;_version=1&amp;_urlVersion=0&amp;_userid=10&amp;md5=0f3169e01fa5c87298ac7b9f84436e73"
       target="_blank">phase 2 trial</a> in just over 1100
      participants, a study that lasted 2&middot;5 years. VLPs of
      the two most important oncogenic HPV types, HPV16 and HPV18,
      were combined in a preventive vaccine. According- to-protocol
      and intention-to-treat analyses showed high efficacy for this
      bivalent vaccine against both the incident and persistent
      HPV16 and HPV18 infections. This efficacy turned out to be
      excellent even though the most sensitive method, vaginal
      self-sampling, was used to define the endpoints.</p>

      <p class="text2">The efficacy of the bivalent vaccine against
      HPV18 infection is particularly important. HPV18 is more
      closely associated with cervical adenocarcinoma, which is
      more difficult to detect by Pap-smear screening. The target
      cells of this HPV type (and others such as HPV45) might be
      endocervical cells. This suggestion is seen in the disease
      associations&mdash;ie, HPV16 is more closely associated with
      cervical squamous-cell carcinoma, and HPV18 is more closely
      associated with cervical adenocarcinoma. From the
      public-health point of view, an intervention effective
      against cervical adenocarcinoma is indeed needed.</p>

      <p class="text2"><span class="yellow">It is also important to
      emphasise that these oncogenic HPV types are associated with
      chronic infections,chronic diseases, and neoplasms in many
      other sites,such as the vulva, vagina, anus, penis, and
      oropharynx.</span><sup><a href="#n7">7,8</a></sup> <span
      class="yellow">The effectiveness of preventive vaccination
      against the oncogenic HPV types against the non-cervical
      HPV-associated neoplasms may be as good as against cervical
      neoplasia.</span></p>

      <p class="text2">The cytological endpoints used by Harper and
      colleagues represent the clinical manifestations of
      infections with the oncogenic HPVs. It is encouraging that
      the bivalent vaccine protects against these cytological
      abnormalities and cervical intraepithelial neoplasia.
      However, long-term passive follow-up of cohorts of vaccinees
      and non-vaccinees by population-based cancer registries is
      needed to prove that HPV vaccination ultimately protects
      against invasive cervical cancer.<sup><a
      href="#n9">9</a></sup></p>

      <p class="text2">Licensure of the HPV vaccine is not far
      away. It will probably be the first licensed vaccine against
      a common sexually transmitted infection. However, the
      implementation should be accomplished in a controlled way
      with community randomised trials. Several questions on the
      effectiveness and the public-health impact of vaccine
      implementation remain unanswered.<sup><a
      href="#n9">9-11</a></sup> How to implement HPV vaccination in
      national vaccination programmes to guarantee high coverage in
      adolescents before they become sexually active? Should both
      girls and boys be vaccinated? How many oncogenic HPV types
      should the vaccine contain? Is resurgence of oncogenic HPV
      types not included in the vaccine a real threat? When is
      booster vaccination required? Harper and colleagues show, for
      instance, that the vaccine induces a robust B-cell response,
      but it is not known whether it induces a significant T-cell
      response. While we trust that the remaining questions can be
      answered, a straightforward message of Harper and colleagues'
      work is that preventive vaccination against the oncogenic HPV
      types will soon be available.</p>

      <p class="text1">*<i>Matti Lehtinen,Jorma Paavonen</i><br />
       <span class="source"><a
      href="http://www.ktl.fi/portal/english/"
      target="_blank">National Public Health Institute</a>,
      Department of Infectious Disease Epidemiology, 00300
      Helsinki, Finland (ML); and Department of Obstetrics and
      Gynaecology, <a href="http://www.helsinki.fi/university/"
      target="_blank">University of Helsinki</a>, Helsinki, Finland
      (JP)<br />
       <a
      href="mailto:Matti.Lehtinen@uta.fi">Matti.Lehtinen@uta.fi</a></span></p>

      <p class="conflicts">We are both principal investigators in
      phase 3 trials of HPV vaccines for Merck and Co and GSK
      Biologicals.</p>

      <ol>
        <li><a id="n1" name="n1"></a>zur Hausen H. Human
        papillomaviruses and cancer. <i>Bibl Haemotol</i>
        1975;<b>43</b>:569-71.</li>

        <li><a id="n2" name="n2"></a>Durst M, Gissmann,L, Ikenberg
        H, zur Hausen H. <a
        href="http://www.pnas.org/cgi/content/abstract/80/12/3812"
        target="_blank">A papillomavirus DNA from a cervical
        carcinoma and its prevalence in cancer biopsy samples from
        different geographic regions</a>. <i>Proc Natl Acad Sci</i>
        USA 1983;<b>80</b>:3812-15.</li>

        <li><a id="n3" name="n3"></a>Lehtinen M, Dillner J, Knekt
        P, et al. <a
        href="http://bmj.bmjjournals.com/cgi/content/abstract/312/7030/537"
         target="_blank">Serological diagnosis of human
        papillomavirus type 16 infection and the risk for
        subsequent development of cervical carcinoma</a>.
        <i>BMJ</i> 1996;<b>312</b>:537-39.</li>

        <li><a id="n4" name="n4"></a>Munoz N, Bosch X, de Sanjose
        S, et al. <a
        href="http://content.nejm.org/cgi/content/abstract/348/6/518"
         target="_blank">Epidemiological classification of human
        papillomavirus types associated with cervical cancer</a>.
        <i>N Engl J Med</i> 2003;<b>348</b>:518-27.</li>

        <li><a id="n5" name="n5"></a>Harro CD, Susana Pang Y-Y,
        Roden R, et al. <a
        href="http://jncicancerspectrum.oupjournals.org/cgi/content/full/jnci;93/4/284"
         target="_blank">Safety and immunogenicity trial in adult
        volunteers of a human papillomavirus 16 L1
        virus-like-particle vaccine</a>. <i>J Natl Cancer Inst</i>
        2001;<b>93</b>:284-92.</li>

        <li><a id="n6" name="n6"></a>Koutsky LA, Ault KA, Wheeler
        CM, for the Proof of Principle Study Investigators. <a
        href="http://content.nejm.org/cgi/content/abstract/347/21/1645"
         target="_blank">A controlled trial of a human
        papillomavirus type 16 vaccine</a>. <i>N Engl J Med</i>
        2002;<b>347</b>:1645-51.</li>

        <li><a id="n7" name="n7"></a>Bjorge T, Engeland A,
        Luostarinen T, et al. <a
        href="http://www.nature.com/cgi-taf/DynaPage.taf?file=/bjc/journal/v87/n1/abs/6600350a.html&amp;dynoptions=doi1104785570"
         target="_blank">A prospective study implicates human
        papillomavirus infection as a risk factor for anal and
        perianal cancer</a>. <i>Br J Cancer</i>
        2002;<b>187</b>:61-64.</li>

        <li><a id="n8" name="n8"></a>Mork J, Lie A-K, Glattre E, et
        al. <a
        href="http://content.nejm.org/cgi/content/abstract/344/15/1125"
         target="_blank">A prospective study on human
        papillomavirus as a risk factor for head and neck cancer
        cancer</a>. <i>N Engl J Med</i>
        2001;<b>344</b>:1125-31.</li>

        <li><a id="n9" name="n9"></a>Lehtinen M, Paavonen J. <a
        href="http://dandini.ingentaselect.com/vl=3078561/cl=60/nw=1/rpsv/cgi-bin/cgi?body=linker&amp;ini=nlm&amp;reqidx=issn=0956-4624vl=14is=12yr=2003mn=Decpg=787">
        Effectiveness of preventive human papillomavirus
        vaccination</a>. <i>Int J STD AIDS</i>
        2003;<b>14</b>:787-92.</li>

        <li><a id="n10" name="n10"></a>Garnett G, Waddel H. Public
        health paradoxes and the epidemiology of human
        papillomavirus vaccination. <i>J Clin Virol</i>
        2000;<b>19</b>:101-12.</li>

        <li><a id="n11" name="n11"></a>Pinto L, Edwards J, Castle
        P, et al. <a
        href="http://www.journals.uchicago.edu/JID/journal/issues/v188n2/30128/30128.html"
         target="_blank">Cellular immune responses to HPV16 L1 in
        healthy volunteers immunized with recombinant HPV16 L1
        virus-like particles</a>. <i>J Infect Dis</i>
        2003;<b>188</b>:327-38.</li>
      </ol>
      <br />
      <br />
    </div>
    <hr />

    Citation:
    <ul>
      <li>Lehtinen M, Paavonen J. Vaccination against human
      papillomaviruses shows great promise. <i>Lancet</i>
      2004;364:1731-2.</li>
    </ul>
    <hr />
    <small>(File created 3 January 2005)</small>

    <center>
      <p class="navlink"><a href="/library/">Return to CIRP
      Library</a></p>
    </center>

    <p>
    <tt>http://www.cirp.org/library/disease/cancer/lehtinen1/</tt></p>
  </body>
</html>
